What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2026-10-23 compared with 2026-07-29 · 226 added, 179 removed, 923 unchanged (30% of the section changed)

2 unchanged sentences

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS

AND COMPREHENSIVE INCOME (LOSS)

(Dollars in thousands, except per share amounts)

Three Months Ended June 30, Six Months Ended June 30,

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

20 unchanged sentences

Diluted 78,577 76,753 77,941 76,637

Comprehensive loss (See Note 13)

Comprehensive income (loss) (See Note 13)

20,536 ( 6,472 ) 10,281 $ ( 519,174 )

3 unchanged sentences

(Dollars in thousands, except per share amounts)

June 30, 2026 December 31, 2025

September 30, 2026 December 31, 2025

Current assets:

39 unchanged sentences

240,000 authorized shares;

92,130 and 92,286 issued at June 30, 2026 and December 31, 2025, respectively

92,098 and 92,286 issued at September 30, 2026 and December 31, 2025, respectively

Additional paid-in capital 1,346,140 1,338,386

Treasury stock, at cost;

14,351 shares and 14,399 shares at June 30, 2026 and December 31, 2025, respectively

14,292 shares and 14,399 shares at September 30, 2026 and December 31, 2025, respectively

( 684,089 ) ( 689,210 )

7 unchanged sentences

(Dollars in thousands)

Six Months Ended June 30,

Nine Months Ended September 30,

OPERATING ACTIVITIES:

Net loss $ ( 134 ) $ ( 509,366 )

Net income (loss) $ 14,717 $ ( 514,770 )

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:

1 unchanged sentence

Non-cash impairment charges — 511,365

Deferred income tax provision (benefit) ( 3,007 ) ( 46,663 )

Deferred income tax benefit ( 2,304 ) ( 55,316 )

Share-based compensation 13,908 12,745

11 unchanged sentences

Other non-current liabilities 171 4,304

Net cash provided by (used in) operating activities 32,605 ( 2,338 )

Net cash provided by operating activities 128,582 38,568

INVESTING ACTIVITIES:

1 unchanged sentence

Purchases of short-term investments ( 30,976 ) ( 8,502 )

Net payments from swaps designated as net investment hedges — ( 432 )

Net cash used in investing activities ( 68,377 ) ( 73,156 )

2 unchanged sentences

Payments on debt ( 126,463 ) ( 69,819 )

Repayments of convertible debt — ( 574,983 )

Payment of debt issuance costs ( 275 ) ( 3,930 )

3 unchanged sentences

Cash taxes paid in net equity settlement ( 1,789 ) ( 2,560 )

Net cash provided by financing activities 7,479 14,238

Net cash (used in) provided by financing activities ( 38,809 ) 3,993

Effect of exchange rate changes on cash and cash equivalents ( 4,183 ) 16,406

Net decrease in cash and cash equivalents ( 20,633 ) ( 28,461 )

Net increase (decrease) in cash and cash equivalents 17,213 ( 14,189 )

Cash and cash equivalents at beginning of period 235,048 246,375

4 unchanged sentences

(Dollars in thousands)

Six Months Ended June 30, 2026

Nine Months Ended September 30, 2026

Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity

2 unchanged sentences

Net loss — — — — — — ( 4,617 ) ( 4,617 )

Other comprehensive income (loss), net of tax — — — — — ( 863 ) — ( 863 )

Other comprehensive loss, net of tax — — — — — ( 863 ) — ( 863 )

Issuance of common stock through employee stock purchase plan 64 1 — — 760 — — 761

8 unchanged sentences

Balance, June 30, 2026 92,130 $ 921 ( 14,351 ) $ ( 686,918 ) $ 1,346,265 $ ( 40,197 ) $ 423,306 $ 1,043,377

Six Months Ended June 30, 2025

Net Income — — — — — — 14,852 14,852

Other comprehensive income, net of tax — — — — — 5,684 — 5,684

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures ( 32 ) — 59 2,829 ( 3,029 ) — — ( 200 )

Share-based compensation — — — — 2,904 — — 2,904

Balance, September 30, 2026 92,098 $ 921 ( 14,292 ) $ ( 684,089 ) $ 1,346,140 $ ( 34,513 ) $ 438,158 $ 1,066,617

Nine Months Ended September 30, 2025

Common Stock Treasury Stock Additional Paid-In Capital Accumulated Other Comprehensive Loss Retained Earnings Total Equity

14 unchanged sentences

Balance, June 30, 2025 92,337 923 ( 14,416 ) ( 690,034 ) 1,328,130 ( 30,907 ) 430,549 1,038,661

Net loss — — — — — — ( 5,404 ) ( 5,404 )

Other comprehensive income, net of tax — — — — — ( 1,068 ) — ( 1,068 )

Issuance of common stock for vesting of share based awards, net of shares withheld for taxes and forfeitures ( 86 ) — — 9 ( 207 ) — — ( 198 )

Share-based compensation — — — — 5,583 — — 5,583

Accelerated shares repurchased — — — — — — — —

Balance, September 30, 2025 92,251 923 ( 14,416 ) ( 690,025 ) 1,333,506 ( 31,975 ) 425,145 1,037,574

The accompanying unaudited notes are an integral part of these condensed consolidated financial statements.

3 unchanged sentences

The terms “we,” “our,” “us,” “Company” and “Integra” refer to Integra LifeSciences Holdings Corporation, a Delaware corporation, and its subsidiaries unless the context suggests otherwise.

In the opinion of management, the June 30, 2026 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented.

In the opinion of management, the September 30, 2026 unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, statement of changes in shareholders’ equity, results of operations and cash flows of the Company for the periods presented.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.

1 unchanged sentence

The consolidated balance sheet as of December 31, 2025 was derived from audited financial statements but does not include all disclosures required by GAAP.

Operating results for the three and six-month period ended June 30, 2026 are not necessarily indicative of the results to be expected for the entire year.

Operating results for the three and nine-months period ended September 30, 2026 are not necessarily indicative of the results to be expected for the entire year.

The preparation of consolidated financial statements is in conformity with GAAP, which requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses.

32 unchanged sentences

Cash and cash equivalents

The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling $ 214.4 million and $ 235.0 million at June 30, 2026 and December 31, 2025, respectively.

The Company had cash and cash equivalents, primarily consisting of cash on-hand, as well as time deposits with original maturities of three months or less and money market funds, which are highly liquid and readily convertible to cash, totaling $ 252.3 million and $ 235.0 million at September 30, 2026 and December 31, 2025, respectively.

Short-term investments

The Company had short-term investments, primarily consisting of time deposits with original maturities between three months and one year, totaling $ 59.7 million and $ 28.7 million at June 30, 2026 and December 31, 2025, respectively.

The short-term investments are valued based on Level 1 measurements in the fair value hierarchy.

14 unchanged sentences

These adjustments relate to the legal right to receive a refund of IEEPA tariffs previously imposed on the Company without appropriate authority.

During the six months ended June 30, 2026, the Company received cash refunds of $ 0.5 million, which reduced the receivable balance.

During the nine months ended September 30, 2026, the Company received cash refunds of $ 16.2 million, which reduced the receivable balance, and recognized cash interest receipts of $ 0.7 million associated with those refunds.

Employee termination benefits

9 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company incurred employee termination costs on restructuring activities in the consolidated statement of operations for the six months ended June 30, 2026 and 2025.

The following table summarizes the activity in the restructuring related accrual balances included within accrued expenses and other current liabilities in the consolidated balance sheet for the six months ended June 30, 2026 and 2025.

Six Months Ended June 30,

The Company incurred employee termination costs related to restructuring activities in the consolidated statement of operations for the nine months ended September 30, 2026 and 2025.

Nine Months Ended September 30,

(Dollars in thousands) 2026 2025

6 unchanged sentences

Segment information

In the third quarter of 2026, the Company renamed its Private Label business in the Tissue Reconstruction reportable segment to Corporate Partnerships.

The business name change did not result in any change to the composition of the reportable segments and has no impact on previously reported financial information.

In the first quarter of 2026, the Company updated the allocation of certain cost and expense information from the Corporate and Other category to the Company’s two reportable segments to align with how the Company’s Chief Operating Decision Maker (“CODM”) reviews and manages the business.

19 unchanged sentences

Upon the authorization, a credit will be issued for the goods returned within a set amount of days from the shipment, which is generally 90 days.

The Company disregards the effects of a financing component if the Company expects, at contract inception, that the period between the transfer and customer payment for the goods or services will be one year or less.

The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company has no significant revenues recognized on payments expected to be received more than one year after the transfer of control of products or services to customers.

Contract Assets and Liabilities

4 unchanged sentences

A portion of the transaction price allocated to the performance obligations to be satisfied in the future periods is recognized as contract liability.

The following table summarizes the changes in the contract asset and liability balances for the six months ended June 30, 2026:

The following table summarizes the changes in the contract asset and liability balances for the nine months ended September 30, 2026:

Dollars in thousands Total

3 unchanged sentences

Contract asset, net of transferred to trade receivables on contracts during the period $ 5,040

Contract asset, June 30, 2026

Contract asset, September 30, 2026

Contract Liability

Contract liability, January 1, 2026

Recognition of revenue included in beginning of year contract liability $ ( 7,310 )

Recognition of revenue included in beginning-of-the-year contract liability $ ( 9,393 )

Contract liability, net of revenue recognized on contracts during the period $ 7,898

Foreign currency translation $ 9

Contract liability, June 30, 2026

As of June 30, 2026, the short-term portion of the contract liability of $ 11.7 million, representing 54 % of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet.

Contract liability, September 30, 2026

As of September 30, 2026, the short-term portion of the contract liability of $ 12.1 million, representing 56 % of unsatisfied or partially unsatisfied performance obligations, is expected to be recognized as revenue within 12 months and is included in current liabilities in the consolidated balance sheet.

The long-term portion of $ 9.4 million, representing the remaining balance to be recognized thereafter, is included in other liabilities in the consolidated balance sheet.

14 unchanged sentences

Disaggregated Revenue

The following table presents revenues disaggregated by the major sources of revenues for the three and six months ended June 30, 2026 and 2025 (dollar amounts in thousands):

Three Months Ended June 30, 2026 Three Months Ended June 30, 2025 Six Months Ended June 30, 2026 Six Months Ended June 30, 2025

The following table presents revenues disaggregated by the major sources of revenues for the three and nine months ended September 30, 2026 and 2025 (dollar amounts in thousands):

Three Months Ended September 30, 2026 Three Months Ended September 30, 2025 Nine Months Ended September 30, 2026 Nine Months Ended September 30, 2025

Neurosurgery $ 214,097 $ 201,563 $ 625,556 $ 601,466

3 unchanged sentences

Wound Reconstruction Solutions 81,529 83,988 242,480 243,514

Private Label 28,187 26,900 57,323 54,110

Corporate Partnerships 25,533 25,491 82,856 79,602

Total Tissue Reconstruction 107,062 109,479 325,336 323,116

2 unchanged sentences

Inventories, net consisted of the following:

Dollars in thousands June 30, 2026 December 31, 2025

Dollars in thousands September 30, 2026 December 31, 2025

Finished goods $ 257,545 $ 262,614

3 unchanged sentences

Goodwill and Other Intangible Assets

Changes in the carrying amount of goodwill for the six-month period ended June 30, 2026 were as follows:

Changes in the carrying amount of goodwill for the nine-month period ended September 30, 2026 were as follows:

Dollars in thousands Specialty Surgery Tissue Reconstruction Total

1 unchanged sentence

Foreign currency translation ( 4,101 ) ( 3,229 ) ( 7,330 )

Goodwill at June 30, 2026

Goodwill at September 30, 2026

$ 340,066 $ 267,761 $ 607,827

4 unchanged sentences

The Company tests for impairment by either performing a qualitative evaluation or a quantitative test.

The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair values of a reporting unit is less than its carrying amount, including goodwill.

The qualitative evaluation is an assessment of factors, including reporting unit specific operating results as well as industry, market and general economic conditions, to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill.

The Company may elect to bypass this qualitative evaluation for some or all of its reporting units and perform a quantitative test.

9 unchanged sentences

Level 3 inputs are supported by limited or no market activity and reflect the Company’s assumptions in measuring fair value.

During the second quarter of 2025, the Company performed a quantitative assessment of its Tissue Reconstruction, Neurosurgery, and Instruments and ENT reporting units in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues.

The Company recognized an aggregate charge of $ 511.4 million in goodwill impairment expense in the consolidated statement of operations in the second quarter of 2025.

During the third quarter of 2026, the Company performed its annual test of its reporting units for impairment.

The Company elected to bypass the qualitative evaluations of its Tissue Reconstruction and Neurosurgery reporting units for impairment and perform quantitative tests.

The Instruments and ENT reporting unit had been deemed fully-impaired during the second quarter of 2025 and was excluded from this evaluation.

The quantitative test for the Tissue Reconstruction reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 13.0 % in the income approach.

The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Reconstruction reporting unit was less than its carrying amount and recognized an impairment of $ 123.3 million.

The Company determined, after performing the quantitative analysis, that the fair value of the Tissue Reconstruction reporting unit was not less than its carrying amount, with 11.3 % headroom.

The quantitative test for the Neurosurgery reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 13.0 % in the income approach.

The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was less than its carrying amount and recognized an impairment of $ 249.0 million.

The quantitative test for the Instruments and ENT reporting unit utilized a terminal growth rate of 2.5 % and a discount rate of 12.0 % in the income approach.

The Company determined, after performing the quantitative analysis, that the fair value of the Instruments and ENT reporting unit was less than its carrying amount and recognized an impairment of $ 139.1 million.

In the third quarter of 2025, the Company performed its annual test of its reporting units for impairment and completed a qualitative evaluation of its Tissue Reconstruction and Neurosurgery reporting units.

The Instruments and ENT reporting unit had been deemed fully-impaired during the second quarter of 2025 and was excluded from this evaluation.

After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair values of the Tissue Reconstruction and Neurosurgery reporting units were greater than their carrying amounts.

Therefore, it was not necessary to perform a quantitative impairment test.

The Company determined, after performing the quantitative analysis, that the fair value of the Neurosurgery reporting unit was not less than its carrying amount, with 15.3 % headroom.

Based on the results of these quantitative tests, the Company recorded no impairment of goodwill for Tissue Reconstruction or Neurosurgery reporting units.

The Company performed a hypothetical sensitivity analysis of the fair value for each reporting unit by increasing the discount rate by 50 basis points, decreasing the terminal growth rate by 50 basis points, and holding all other assumptions constant, which resulted in a decrease to the estimated fair value of the Tissue Reconstruction reporting unit by 3.8 % and a decrease to the estimated fair value of the Neurosurgery reporting unit by 3.0 %.

Based on the results of the hypothetical sensitivity analyses, the estimated fair values of both reporting units remained greater than their carrying values, and no goodwill impairment charge would have been required.

The Company recognized an aggregate charge of $ 511.4 million in goodwill impairment expense in the consolidated statement of operations during 2025.

Other Intangible Assets

The components of the Company’s identifiable intangible assets were as follows:

June 30, 2026

September 30, 2026

Dollars in thousands Weighted

27 unchanged sentences

The Company may elect to bypass this qualitative evaluation and perform a quantitative test.

During the second quarter of 2025 the Company performed a quantitative assessment of its Codman tradename intangible asset in accordance with ASC 350 due to the decrease in the price per share of the Company’s common stock related to a number of factors including recent tariff changes that have created broad economic uncertainty and the impact of quality, operational, and supply issues.

During the third quarter of 2026, the Company performed its annual test of its intangible assets with indefinite lives for impairment.

The Company elected to bypass the qualitative evaluation for its Codman tradename intangible asset and perform a quantitative test.

In performing this test, the Company utilized a discount rate of 14.0 %.

1 unchanged sentence

Based on the results of the quantitative test, the Company recorded no impairment to the Codman tradename intangible asset.

In the third quarter of 2025, the Company performed its annual test of its intangible assets with indefinite lives for impairment and completed a qualitative evaluation of its Codman tradename intangible asset.

After performing the qualitative analysis, the Company concluded that it was more likely than not that the fair value of the Codman tradename intangible asset was greater than its carrying amount.

Therefore, it was not necessary to perform a quantitative impairment test.

The Company did not recognize any impairment charges on its intangible assets with indefinite lives during 2025.

Intangible Assets with Definite Lives

Developed technologies and other definite-lived intangible assets are amortized over their estimated useful lives either using the straight-line method or, if reliably determinable, based on the pattern of which the economic benefit of the asset is expected to be utilized.

Developed technologies and other definite-lived intangible assets are amortized over their estimated useful lives either using the straight-line method or, if reliably determinable, based on the pattern in which the economic benefit of the asset is expected to be utilized.

Definite-lived intangible assets are periodically evaluated for impairment in accordance with FASB Topic 360, Property, Plant and Equipment (“ASC 360”) whenever events or changes in circumstances indicate that a definite-lived intangible asset’s carrying value may not be recoverable.

Total amortization of intangible assets for the three and six months ended June 30, 2026 was $ 27.0 million and $ 54.0 million, respectively.

Total amortization of intangible assets for the three and nine months ended September 30, 2026 was $ 26.8 million and $ 80.8 million, respectively.

Of this amount, $ 23.1 million and $ 69.5 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold.

Total amortization of intangible assets for the three and six months ended June 30, 2025 was $ 26.8 million and $ 53.3 million, respectively.

Total amortization of intangible assets for the three and nine months ended September 30, 2025 was $ 26.9 million and $ 80.1 million, respectively.

Of this amount, $ 23.1 million and $ 69.0 million, respectively, was related to amortization of technology based intangibles and included in cost of goods sold.

Based on quarter-end exchange rates, amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $ 26.7 million for the remainder of 2026, $ 106.1 million in 2027, $ 102.5 million in 2028, $ 97.2 million in 2029, $ 91.1 million in 2030, $ 88.1 million in 2031 and $ 357.1 million thereafter.

Amendment to the Seventh Amended and Restated Credit Agreement

Amendment to the Seventh Amended and Restated Senior Credit Agreement

On March 24, 2023, the Company entered into the March 2023 Amendment of the Senior Credit Facility with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent.

2 unchanged sentences

subsidiaries, excluding intangible assets.

The Senior Credit Facility is subject to various financial and negative covenants and, at June 30, 2026, the Company was in compliance with all such covenants.

The Senior Credit Facility is subject to various financial and negative covenants and, at September 30, 2026, the Company was in compliance with all such covenants.

On June 6, 2025, in response to the risks and uncertainties surrounding the Company’s future results of operations due to tariffs, the Company entered into the June 2025 Amendment of the Senior Credit Facility (the “June 2025 Amendment”) with a syndicate of lending banks with Bank of America, N.A., as Administrative Agent.

4 unchanged sentences

Fiscal Quarter Ending Maximum Consolidated Total Leverage Ratio

June 30, 2025 through June 30, 2026 5.00 to 1.00

September 30, 2026 4.75 to 1.00

18 unchanged sentences

The terms of the Senior Credit Facility limit the amount of dividends the Company may pay.

At June 30, 2026 and December 31, 2025, there wa s $ 1,075.0 million and $ 1,045.0 million, respectively, ou tstanding under the revolving credit facility component of the Senior Credit Facility and $ 707.2 million and $ 726.6 million, respectively, outstanding under the term loan component of the Senior Credit Facility.

At September 30, 2026 and December 31, 2025, there wa s $ 1,050.0 million and $ 1,045.0 million, respectively, ou tstanding under the revolving credit facility component of the Senior Credit Facility and $ 697.5 million and $ 726.6 million, respectively, outstanding under the term loan component of the Senior Credit Facility.

The weighted average interest rate on the outstanding borrowings under the Senior Credit Facility was 5.6 % and 5.7 %, respectively.

As of June 30, 2026 and December 31, 2025, there was $ 43.6 million and $ 38.8 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.

As of June 30, 2026 and December 31, 2025, letters of credit outstanding to taled $ 3.0 million.

There were no amounts drawn under the letters of credit outstanding as of June 30, 2026.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

As of September 30, 2026 and December 31, 2025, there was $ 48.4 million and $ 38.8 million, respectively, of the term loan component of the Senior Credit Facility classified as current on the condensed consolidated balance sheet.

As of September 30, 2026 and December 31, 2025, letters of credit outstanding to taled $ 3.1 million and $ 3.0 million, respectively.

There were no amounts drawn under the letters of credit outstanding as of September 30, 2026.

Contractual repayments of the term loan component of the Senior Credit Facility are due as follows:

As of June 30, 2026

As of September 30, 2026

Principal Repayment

1 unchanged sentence

Remainder of 2026

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Future interest payments on the term loan component of the Senior Credit Facility based on current interest rates are expected to approximate $ 9.8 million for the remainder of 2026, $ 37.7 million in 2027 and $ 8.2 million in 2028.

20 unchanged sentences

An occurrence of an event of default or a termination event under this Securitization Agreement may give rise to the right of its counterparty to terminate this facility.

As of June 30, 2026, the Company was in compliance with the covenants and none of the termination events had occurred.

As of September 30, 2026, the Company was in compliance with the covenants and none of the termination events had occurred.

On April 10, 2026, the Company entered into an amendment to the Securitization Facility Agreement with a syndicate of lending banks with PNC Bank, N.A., as Administrative Agent (the “2026 Securitization Facility Amendment”).

2 unchanged sentences

The Company incurred approximately $ 0.3 million of new issuance costs associated with the 2026 Securitization Facility Amendment which will be amortized over the remaining term of the Securitization Agreement as amended.

At June 30, 2026 and December 31, 2025, the Company had $ 92.6 million and $ 87.8 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 5.0 % and 4.8 %, respectively.

At September 30, 2026 and December 31, 2025, the Company had $ 81.2 million and $ 87.8 million, respectively, of outstanding borrowings under its Securitization Facility with an interest rate of 5.2 % and 4.8 %, respectively.

Debt Issuance Costs

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Debt issuance costs associated with the Senior Credit Facility (other than the revolving credit facility component) are presented as a reduction to the carrying value of the related debt.

Debt issuance costs associated with the revolving credit facility component of the Senior Credit Facility are capitalized within other long-term assets on the consolidated balance sheet.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Estimated Fair Value of Debt Measurements

The carrying amounts and the estimated fair values of debt as of June 30, 2026 and December 31, 2025 are as follows:

June 30, 2026 December 31, 2025

The carrying amounts and the estimated fair values of debt as of September 30, 2026 and December 31, 2025 are as follows:

September 30, 2026 December 31, 2025

Fair Value Measurement Carrying Value Estimated Fair Value Carrying Value Estimated Fair Value

6 unchanged sentences

Total debt $ 1,826,588 $ 1,821,283 $ 1,856,106 $ 1,855,498

Debt Refinancing

In October 2026, the Company completed a comprehensive refinancing of its Senior Credit Facility through the execution of a new Amended and Restated Credit Agreement (the “October 2026 Credit Agreement”) and a private offering of $ 450.0 million aggregate principal amount of 9.5 % Senior Secured Notes due 2033 (the “2033 Notes”).

The refinancing extends the Company’s debt maturity profile, enhances liquidity, and provides additional financial flexibility to support ongoing operations and strategic priorities.

Proceeds from the October 2026 Credit Agreement and 2033 Notes were used to refinance the existing Senior Credit Facility and pay related transaction fees and expenses.

The October 2026 Credit Agreement includes a Term Loan A facility of $ 600.0 million with a maturity date of October 19, 2031, a Term Loan B facility of $ 450.0 million with a maturity date of October 19, 2033, and a revolving credit facility of $ 600.0 million with a maturity date of October 19, 2031.

The October 2026 Credit Agreement is collateralized by substantially all of the assets of the Company’s U.S.

subsidiaries.

The Term Loan A and the revolving credit facility are subject to various financial and negative covenants, including leverage and interest coverage requirements.

Under the terms of the October 2026 Credit Agreement, the Company is required to maintain a minimum Consolidated Total Leverage Ratio (as defined in the October 2026 Credit Agreement) for the period of four consecutive fiscal quarters ending on such date based on the following:

Fiscal Quarter Ending Maximum Consolidated Total Leverage Ratio

September 30, 2026 4.75 to 1.00

December 31, 2026 4.50 to 1.00

March 31, 2027 through December 31, 2027 4.25 to 1.00

The last day of each fiscal quarter thereafter 4.00 to 1.00

The 2033 Notes mature on November 1, 2033 and bear interest at the rate of 9.5 % per annum payable semi-annually in arrears on May 1 and November 1 of each year, beginning on May 1, 2027.

The 2033 Notes will be redeemable, in whole or in part, at the Company’s option, at any time on or after November 1, 2029, at the following redemption prices, plus accrued and unpaid interest thereon, to, but excluding, the redemption date:

Period Redemption price

on the principal amount of 2033 Notes to be redeemed

November 1, 2029 through October 31, 2030 104.75 %

November 1, 2030 through October 31, 2031 102.38 %

November 1, 2031 and thereafter 100.00 %

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Derivative Instruments

5 unchanged sentences

Additionally, the Company entered into a basis swap where the Company receives Term SOFR and pays daily compounded SOFR to convert the portfolio of swaps from daily compounded SOFR to Term SOFR.

The Company held the following interest rate swaps as of June 30, 2026 and December 31, 2025 (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

The Company held the following interest rate swaps as of September 30, 2026 and December 31, 2025 (dollar amounts in thousands):

September 30, 2026 December 31, 2025 September 30, 2026 December 31, 2025

Hedged Item Notional Amount Effective Date Termination Date Fixed Interest Rate Estimated Fair Value

10 unchanged sentences

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to interest income from AOCI as of June 30, 2026 within the next twelve months is $ 20.2 million.

The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2026 within the next twelve months is $ 24.7 million.

The Company has designated these derivative instruments as cash flow hedges.

1 unchanged sentence

If the hedged cash flow does not occur, or if it becomes probable that it will not occur, the Company will reclassify the remaining amount of any gain or loss on the related cash flow hedge recorded in AOCI to interest expense at that time.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Foreign Currency Hedging

6 unchanged sentences

For contracts not designated as hedging instruments, the changes in fair value of the contracts are recognized in other income, net in the consolidated statements of operation, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities.

The success of the Company’s hedging anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility.

The success of the Company’s hedging activities depends on anticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activities during periods of currency volatility.

In addition, changes in currency exchange rates related to any unhedged transactions may affect earnings and cash flows.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Cross-Currency Rate Swaps

14 unchanged sentences

As the principal outstanding decreases on the intercompany loans, the aggregate notional amount of the related cross-currency swaps will decrease by a corresponding amount.

The Company held the following cross-currency rate swaps as of June 30, 2026 and December 31, 2025 (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

The Company held the following cross-currency rate swaps as of September 30, 2026 and December 31, 2025 (dollar amounts in thousands):

September 30, 2026 December 31, 2025 September 30, 2026 December 31, 2025

Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value

11 unchanged sentences

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of June 30, 2026 within the next twelve months is $ 10.1 million.

For the three and six months ended June 30, 2026, the Company recorded gains of $ 7.2 million and $ 13.1 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and six months ended June 30, 2025, the Company recorded losses of $( 40.6 ) million and $( 49.8 ) million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and six months ended June 30, 2026, the Company recorded gains of $ 3.5 million and $ 7.0 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

For the three and six months ended June 30, 2025, the Company recorded gains of $ 2.3 million and $ 3.5 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

The estimated gain that is expected to be reclassified to other income (expense), net from AOCI as of September 30, 2026 within the next twelve months is $ 11.4 million.

For the three and nine months ended September 30, 2026, the Company recorded gains of $ 14.8 million and $ 31.3 million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and nine months ended September 30, 2025, the Company recorded a gain of $ 2.8 million and a loss of $( 47.1 ) million, respectively, in other income, net related to change in fair value related to the foreign currency rate translation to offset the gains and losses, respectively, recognized on the intercompany loans.

For the three and nine months ended September 30, 2026, the Company recorded gains of $ 3.7 million and $ 10.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

For the three and nine months ended September 30, 2025, the Company recorded gains of $ 2.3 million and $ 5.7 million, respectively, in other income, net included in the consolidated statements of operations related to the interest rate differential of the cross-currency swaps.

Net Investment Hedges

7 unchanged sentences

The new cross-currency swap agreement was designated as a net investment hedge to partially offset the effects of foreign currency on foreign subsidiaries.

The Company held the following cross-currency rate swaps designated as net investment hedges as of June 30, 2026 and December 31, 2025, respectively (dollar amounts in thousands):

June 30, 2026 December 31, 2025 June 30, 2026 December 31, 2025

The Company held the following cross-currency rate swaps designated as net investment hedges as of September 30, 2026 and December 31, 2025, respectively (dollar amounts in thousands):

September 30, 2026 December 31, 2025 September 30, 2026 December 31, 2025

Effective Date Termination Date Fixed Rate Aggregate Notional Amount Fair Value

11 unchanged sentences

Total $ ( 65,563 ) $ ( 82,199 )

The net investment hedges are carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to interest income from AOCI as of June 30, 2026 within the next twelve months is $ 10.7 million.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The net investment hedges are carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

The estimated gain that is expected to be reclassified to interest income from AOCI as of September 30, 2026 within the next twelve months is $ 10.6 million.

Foreign Currency Forward Contracts

1 unchanged sentence

These contracts typically settle at various dates within twelve months of execution.

As of June 30, 2026, the notional amount of foreign currency forward contracts was CHF 19.6 million.

As of September 30, 2026, the notional amount of foreign currency forward contracts was CHF 18.2 million.

The foreign currency forward contracts are carried on the consolidated balance sheet at fair value and changes in the fair values were recorded as unrealized gains or losses in AOCI.

The changes in fair value will be recognized into earnings as a component of cost of sales when the forecasted-transaction occurs.

For the three months ended June 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.3 million and $( 0.4 ) million, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.2 ) million and $( 0.2 ) million, respectively, within other income (expense), net.

For the six months ended June 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.8 million and an immaterial amount, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.3 ) million and $( 0.4 ) million, respectively, within other income (expense), net.

For the three months ended September 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.1 million and $ 0.2 million, respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.2 ) million and $( 0.2 ) million, respectively, within other income (expense), net.

For the nine months ended September 30, 2026 and 2025, amounts reclassified to earnings included (i) the effective hedge component amounts of $ 0.9 million and $ 0.2 million respectively, within cost of goods sold, and (ii) forward‑points amortization of $( 0.5 ) million and $( 0.6 ) million, respectively, within other income (expense), net.

Related gain/loss amounts recognized in AOCI and earnings are presented in the Effects of Derivative Instruments table below.

9 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025:

The following table summarizes the fair value for derivatives designated as hedging instruments in the condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025:

Fair Value as of

Location on Balance Sheet (1) :

June 30, 2026 December 31, 2025

September 30, 2026 December 31, 2025

Dollars in thousands

29 unchanged sentences

Effects of Derivative Instruments

The following presents the effect of derivative instruments designated as cash flow hedges and net investment hedges on the accompanying condensed consolidated statement of operations during the three and six months ended June 30, 2026 and 2025:

Dollars in thousands Balance in AOCI

6 unchanged sentences

Statements of

Three Months Ended June 30, 2026

Three Months Ended September 30, 2026

Cash Flow Hedges

5 unchanged sentences

$ ( 75,178 ) $ 38,828 $ 28,864 $ ( 65,214 )

Three Months Ended June 30, 2025

Three Months Ended September 30, 2025

Cash Flow Hedges

13 unchanged sentences

Statements of

Six Months Ended June 30, 2026

Nine Months Ended September 30, 2026

Cash Flow Hedges

5 unchanged sentences

$ ( 71,750 ) $ 69,579 $ 63,043 $ ( 65,214 )

Six Months Ended June 30, 2025

Nine Months Ended September 30, 2025

Cash Flow Hedges

10 unchanged sentences

These contracts typically settle at various dates within twelve months of execution.

As of June 30, 2026, the notional amounts totaled CNH 90.0 million, CHF 12.0 million, and EUR 5.0 million equivalent to $ 13.3 million, $ 15.1 million, and $ 5.8 million, respectively.

As of September 30, 2026, the Company did not have any derivative instruments outstanding that were not designated as hedging instruments.

As of December 31, 2025, the fair value of the foreign currency swaps not designated as hedges was $ 1.0 million.

In 2021, the Company entered into a foreign currency swap, with a notional amount of JPY 800.0 million, equivalent to $ 7.3 million, to mitigate the risk from fluctuations in foreign currency exchange rates associated with an intercompany loan denominated in Japanese yen.

2 unchanged sentences

In connection with the settlement of the related intercompany loan, the Company fully settled and unwound the derivative during the second quarter of 2026.

The fair value of the foreign currency swaps not designated as hedges was $( 0.5 ) million and $ 1.0 million as of June 30, 2026 and December 31, 2025, respectively.

The following table summarizes the gains and losses on derivative instruments not designated as hedges on the condensed consolidated statements of income, which was included in other income:

Dollars in thousands Three Months Ended June 30, Six Months Ended June 30,

Dollars in thousands Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

3 unchanged sentences

Stock Based Compensation

As of June 30, 2026, the Company had stock options, restricted stock awards, performance stock units and restricted stock units outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).

Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date of grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change-in-control provisions within their grant agreements.

As of September 30, 2026, the Company had stock options, restricted stock awards, performance stock units and restricted stock units outstanding under the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan, as amended (the “2003 Plan”).

Stock options issued under the 2003 Plan become exercisable over specified periods, generally within four years from the date of grant for officers and employees, within one year from date the grant for directors which generally expire eight years from the grant date for employees, and from six to ten years for directors and certain executive officers, except in certain instances that result in accelerated vesting due to death, disability, retirement age or change-in-control provisions within their grant agreements.

The Company values stock option grants using the binomial distribution model.

2 unchanged sentences

Stock Options

As of June 30, 2026, there were approximately $ 8.2 million of total unrecognized compensation costs related to unvested stock options.

As of September 30, 2026, there were approximately $ 7.4 million of total unrecognized compensation costs related to unvested stock options.

These costs are expected to be recognized over a weighted-average period of approximately three years .

There were 765,840 stock options granted during the six months ended June 30, 2026.

For the six months ended June 30, 2026, the weighted average grant date fair value for stock options granted was $ 8.28 per option.

There were 765,840 stock options granted during the nine months ended September 30, 2026.

For the nine months ended September 30, 2026, the weighted average grant date fair value for stock options granted was $ 8.28 per option.

Restricted Stock and Performance Stock

2 unchanged sentences

The Company expenses the fair value of restricted stock awards and restricted stock units on a straight-line basis over the requisite service period.

As of June 30, 2026, there was approximately $ 44.4 million of total unrecognized compensation costs related to these unvested awards.

As of September 30, 2026, there was approximately $ 35.6 million of total unrecognized compensation costs related to these unvested awards.

The Company expects to recognize these costs over a weighted-average period of approximately two years .

The Company granted 2,909,403 restricted stock units and 1,149,357 performance stock units during the six months ended June 30, 2026.

For the six months ended June 30, 2026, the weighted average grant date fair value for restricted stock units and performance stock units granted was $ 10.74 and $ 9.61 per award, respectively.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company granted 2,945,566 restricted stock units and 1,154,947 performance stock units during the nine months ended September 30, 2026.

For the nine months ended September 30, 2026, the weighted average grant date fair value for restricted stock units and performance stock units granted was $ 10.82 and $ 9.65 per award, respectively.

The Company also maintains an Employee Stock Purchase Plan (the “ESPP”), which provides eligible employees with the opportunity to acquire shares of common stock at periodic intervals by means of accumulated payroll deductions.

The ESPP is a non-compensatory plan based on its terms.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Retirement Plans

The Company has various defined benefit plans which cover certain employees in France, Japan, Germany and Switzerland.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and six months ended June 30, 2026 were $ 0.4 million and $ 0.9 million.

The components of the net periodic benefit costs other than the service cost component of $ 1.0 million and $ 2.0 million for the three and six months ended June 30, 2026 are included in other income, net in the consolidated statements of operations.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and six months ended June 30, 2025 were $ 0.4 million and $ 0.7 million.

The components of the net periodic benefit costs other than the service cost component of $ 0.8 million and $ 1.6 million for the three and six months ended June 30, 2025 are included in other income, net in the consolidated statements of operations.

The estimated fair values of plan assets were $ 69.7 million and $ 71.7 million as of June 30, 2026 and December 31, 2025, respectively.

The net plan assets of the pension plans are invested in common trusts as of June 30, 2026 and December 31, 2025.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2026 were $ 0.4 million and $ 1.3 million.

The components of the net periodic benefit costs other than the service cost component of $ 1.0 million and $ 3.0 million for the three and nine months ended September 30, 2026 are included in other income, net in the consolidated statements of operations.

Net periodic benefit costs for the Company’s defined benefit pension plans for the three and nine months ended September 30, 2025 were $ 0.4 million and $ 1.1 million.

The components of the net periodic benefit costs other than the service cost component of $ 0.8 million and $ 2.5 million for the three and nine months ended September 30, 2025 are included in other income, net in the consolidated statements of operations.

The estimated fair values of plan assets were $ 67.5 million and $ 71.7 million as of September 30, 2026 and December 31, 2025, respectively.

The net plan assets of the pension plans are invested in common trusts as of September 30, 2026 and December 31, 2025.

Common trusts are classified as Level 2 in the fair value hierarchy.

5 unchanged sentences

Assets of the Company’s deferred compensation plan are included in other current assets and recorded at fair value based on their quoted market prices.

The fair value of these assets were $ 8.1 million and $ 7.9 million as of June 30, 2026 and December 31, 2025, respectively.

The fair value of these assets were $ 8.1 million and $ 7.9 million as of September 30, 2026 and December 31, 2025, respectively.

Offsetting liabilities relating to the deferred compensation plan are included in other liabilities.

1 unchanged sentence

The Company leases administrative, manufacturing, research and distribution facilities, equipment and vehicles through operating lease agreements.

The Company has no finance leases as of June 30, 2026.

The Company has no finance leases as of September 30, 2026.

Many of the Company’s facility leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common-area or other maintenance costs).

4 unchanged sentences

As most of the Company’s leases do not provide an implicit rate, the Company uses a collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments.

Total operating lease expense for the six months ended June 30, 2026 and June 30, 2025 was $ 13.0 million and $ 11.9 million, respectively, which includes $ 0.1 million in related party operating lease expense.

Total operating lease expense for the nine months ended September 30, 2026 and September 30, 2025 was $ 19.7 million and $ 17.8 million, respectively, which includes $ 0.2 million in related party operating lease expense.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

1 unchanged sentence

Supplemental balance sheet information related to operating leases were as follows:

Dollars in thousands, except lease term and discount rate June 30, 2026 December 31, 2025

Dollars in thousands, except lease term and discount rate September 30, 2026 December 31, 2025

ROU assets $ 136,134 $ 140,568

10 unchanged sentences

Leased equipment 5.5 % 6.9 %

Supplemental cash flow information related to leases for the six months ended June 30, 2026 and 2025 were as follows:

Dollars in thousands June 30, 2026 June 30, 2025

Supplemental cash flow information related to leases for the nine months ended September 30, 2026 and 2025 were as follows:

Dollars in thousands September 30, 2026 September 30, 2025

Cash paid for amounts included in the measurement of lease liabilities:

2 unchanged sentences

Operating leases $ 6,119 $ 6,493

Future minimum lease payments under operating leases at June 30, 2026 were as follows:

Future minimum lease payments under operating leases at September 30, 2026 were as follows:

Dollars in thousands Related Parties Third Parties Total

12 unchanged sentences

Long-term lease liabilities 161,091

There were no future minimum lease payments under finance leases at June 30, 2026.

There were no future minimum lease payments under finance leases at September 30, 2026.

Related Party Leases

5 unchanged sentences

Treasury Stock

As of June 30, 2026 and December 31, 2025, there were 14.4 million and 14.4 million shares of treasury stock outstanding with a cost of $ 686.9 million and $ 689.2 million, respectively, at a weighted average cost per share of $ 47.86 for both periods.

As of September 30, 2026 and December 31, 2025, there were 14.3 million and 14.4 million shares of treasury stock outstanding with a cost of $ 684.1 million and $ 689.2 million, respectively, at a weighted average cost per share of $ 47.86 for both periods.

On December 31, 2025, the Company’s share repurchase program expired.

2 unchanged sentences

The following table provides a summary of the Company’s effective tax rate:

Three Months Ended June 30, Six Months Ended June 30,

Three Months Ended September 30, Nine Months Ended September 30,

2026 2025 2026 2025

Reported tax rate 5.2 % 20.8 % 18.2 % 9.3 %

The Company’s effective income tax rates for the three months ended June 30, 2026 and 2025 were 5.5 % and 8.8 %, respectively.

The 2026 effective tax rate was primarily impacted by tax benefits associated with returns filed in certain foreign jurisdictions, as well as the jurisdictional mix of income, including its impact on the Company’s net Controlled Foreign Corporation tested income (“NCTI”) inclusion, formerly referred to as Global Intangible Low Taxed Income (“GILTI”).

The 2025 effective tax rate was primarily impacted by a partially non-deductible goodwill impairment charge, NCTI, and additional taxes related to global minimum tax requirements in certain foreign jurisdictions, partially offset by tax benefits from operating losses in certain jurisdictions.

The Company’s effective income tax rates for the six months ended June 30, 2026 and 2025 were 105.7 % and 9.2 %, respectively.

The 2026 effective tax rate was primarily impacted by tax expense related to a shortfall from stock-based compensation due to market conditions, partially offset by a tax benefit from returns filed in certain foreign jurisdictions.

The 2025 effective tax rate was primarily impacted by a partially non-deductible goodwill impairment charge, GILTI, and additional taxes related to global minimum tax requirements in certain foreign jurisdictions, partially offset by tax benefits from operating losses in certain jurisdictions.

The Company’s effective income tax rates for the three months ended September 30, 2026 and 2025 were 5.2 % and 20.8 %, respectively.

The 2026 effective tax rate was primarily driven by the jurisdictional mix of income, partially offset by tax expense associated with returns filed in certain jurisdictions.

The Company’s effective income tax rates for the nine months ended September 30, 2026 and 2025 were 18.2 % and 9.3 %, respectively.

The 2026 effective tax rate was primarily impacted by the jurisdictional mix of income and tax benefits in certain foreign jurisdictions, offset by tax expense related to a shortfall from stock-based compensation due to market conditions.

The 2025 effective tax rate was primarily impacted by a partially non-deductible goodwill impairment charge.

Changes in tax laws or regulations in the jurisdictions in which the Company operates could impact its effective tax rate.

2 unchanged sentences

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”), was enacted in the U.S.

The OBBBA includes several tax law changes, including extensions of certain 2017 Tax Cuts and Jobs Act provisions, immediate expensing of certain research and development costs, and changes to interest expense deduction limitations.

The OBBBA includes several tax law changes, including permanent extensions of certain 2017 Tax Cuts and Jobs Act provisions, immediate expensing of certain research and development costs, and changes to interest expense deduction limitations.

The Company continues to monitor tax legislation enacted by foreign jurisdictions in response to the Organization of Economic Cooperation and Development’s (“OECD”) Pillar Two global minimum tax framework.

4 unchanged sentences

Basic and diluted net loss per share was as follows:

Three Months Ended June 30, Six Months Ended June 30,

Three Months Ended September 30, Nine Months Ended September 30,

Dollars in thousands, except per share amounts 2026 2025 2026 2025

15 unchanged sentences

For periods in which the Company generated a net loss, the Company does not include the potential impact of dilutive securities in diluted net loss per share, as the impact of these items is anti-dilutive.

Common stock of approximately 1.8 million and 1.5 million shares at June 30, 2026 and 2025, res pectively, were not included in the computation of diluted net income and diluted net loss per share, respectively, because their effect would have been anti-dilutive.

Approximately 1.5 million shares of common stock as of September 30, 2026 and 2025 were excluded from the computation of diluted net income (loss) per share because their inclusion would have been anti-dilutive.

Accumulated Other Comprehensive Loss

Comprehensive loss for the three and six months ended June 30, 2026 and 2025:

Three Months Ended June 30, Six Months Ended June 30,

Comprehensive loss for the three and nine months ended September 30, 2026 and 2025:

Three Months Ended September 30, Nine Months Ended September 30,

Dollars in thousands 2026 2025 2026 2025

3 unchanged sentences

Pension liability adjustment, net of tax ( 193 ) ( 167 ) ( 559 ) ( 483 )

Comprehensive loss, net $ ( 4,775 ) $ ( 490,874 ) $ ( 10,254 ) $ ( 512,702 )

Comprehensive income (loss), net $ 20,536 $ ( 6,472 ) $ 10,281 $ ( 519,174 )

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Changes in accumulated other comprehensive loss by component between December 31, 2025 and June 30, 2026 are presented in the table below, net of tax:

Changes in accumulated other comprehensive loss by component between December 31, 2025 and September 30, 2026 are presented in the table below, net of tax:

Dollars in thousands Gains and Losses on Derivatives Defined Benefit Pension Items Foreign Currency Items Total

4 unchanged sentences

Net current-period other comprehensive (loss) ( 8,377 ) ( 559 ) 4,500 ( 4,436 )

Balance at June 30, 2026

Balance at September 30, 2026

$ 7,571 $ 4,425 $ ( 46,509 ) $ ( 34,513 )

For the six months ended June 30, 2026, the Company reclassified gains of $ 15.8 million and $ 11.5 million from AOCI to other income and interest income, respectively.

For the nine months ended September 30, 2026, the Company reclassified gains of $ 33.6 million and $ 17.3 million from AOCI to other income and interest income, respectively.

Additionally, the Company reclassified a loss of $ 0.3 million from AOCI to cost of goods sold.

2 unchanged sentences

Resources are allocated and performance is assessed by the Company’s President and Chief Executive Officer, which the Company has determined to be the CODM.

During the six months ended June 30, 2026, the Company renamed its two reportable segments to better align with the reportable segments’ business activities, structures, and strategies.

During the nine months ended September 30, 2026, the Company renamed its two reportable segments to better align with the reportable segments’ business activities, structures, and strategies.

The reportable segment name change did not result in any change to the composition of the reportable segments and has no impact on previously reported financial information.

3 unchanged sentences

and (iii) the ENT Solutions business, which includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, as well as surgical navigation systems.

• The Tissue Reconstruction reportable segment operations consists of the Wound Reconstruction Solutions business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products.

The Tissue Reconstruction segment also includes the Company’s private label business which performs contract manufacturing for third parties.

• The Tissue Reconstruction reportable segment operations consist of the Wound Reconstruction Solutions business, which sells offerings such as skin and wound repair, plastics and surgical reconstruction products and nerve and tendon repair products.

The Tissue Reconstruction segment also includes the Company’s Corporate Partnerships business which performs contract manufacturing for third parties.

The Corporate and Other category includes a portion of various executive, finance, human resource, information systems and legal functions which are not allocated to the reportable segments.

During the six months ended June 30, 2026, the Company updated the allocation of certain cost and expense information that the CODM regularly reviews to evaluate performance for decision-making purposes from the Corporate and Other category to the Company’s reportable segments to align with how the CODM reviews and manages the business.

During the nine months ended September 30, 2026, the Company updated the allocation of certain cost and expense information that the CODM regularly reviews to evaluate performance for decision-making purposes from the Corporate and Other category to the Company’s reportable segments to align with how the CODM reviews and manages the business.

As a result of this update, the Company retrospectively recast prior period results, by reportable segment, to conform to the current period presentation.

5 unchanged sentences

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Net sales and profit by each reportable segment for the three and six months ended June 30, 2026 and 2025 are as follows:

Three Months Ended June 30, 2026 Six Months Ended June 30, 2026

Net sales and profit by each reportable segment for the three and nine months ended September 30, 2026 and 2025 are as follows:

Three Months Ended September 30, 2026 Nine Months Ended September 30, 2026

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Specialty Surgery Tissue Reconstruction Corporate and Other Total

10 unchanged sentences

Income before income taxes $ 15,664 $ 17,999

Three Months Ended June 30, 2025 Six Months Ended June 30, 2025

Three Months Ended September 30, 2025 Nine Months Ended September 30, 2025

Dollars in thousands Specialty Surgery Tissue Reconstruction Corporate and Other Total Specialty Surgery Tissue Reconstruction Corporate and Other Total

9 unchanged sentences

Total cost and expenses 203,801 98,053 88,447 390,301 1,018,396 426,598 271,736 1,716,730

Operating loss $ ( 302,192 ) $ ( 119,352 ) ( 91,130 ) ( 512,674 ) $ ( 229,973 ) $ ( 114,908 ) $ ( 183,290 ) ( 528,171 )

Operating income (loss) $ 88,782 $ 11,426 ( 88,447 ) 11,761 $ ( 141,192 ) $ ( 103,482 ) $ ( 271,736 ) ( 516,410 )

Interest income 4,982 14,112

Interest expense ( 22,725 ) ( 62,582 )

Other income, net ( 1,946 ) ( 2,090 )

Other loss, net ( 842 ) ( 2,932 )

Loss before income taxes $ ( 6,824 ) $ ( 567,812 )

(1) The amounts reported for the three and six months ended June 30, 2025 have been retrospectively recast to reflect the realignment of certain cost and expense information as discussed in Note 1.

(1) The amounts reported for the three and nine months ended September 30, 2025 have been retrospectively recast to reflect the realignment of certain cost and expense information as discussed in Note 1.

Basis of Presentation .

5 unchanged sentences

Total revenue by major geographic area consisted of the following:

Three Months Ended June 30, Six Months Ended June 30,

Three Months Ended September 30, Nine Months Ended September 30,

Dollars in thousands 2026 2025 2026 2025

19 unchanged sentences

The arbitration was held in September 2025.

On April 15, 2026, the arbitration tribunal issued its decision finding in Integra’s favor on all claims and awarding the Company its attorneys’ fees and costs to be paid by Fortis.

On April 15, 2026, the arbitration tribunal issued its decision finding in Integra’s favor on all claims and awarding the Company its attorneys’ fees and costs, a portion of which has been received as of September 30, 2026.

On September 12, 2023, a securities class action complaint, captioned Pembroke Pines Firefighters & Police Officers Pension Fund v.

23 unchanged sentences

In connection with the Company’s October 2024 acquisition of Durepair Regeneration Matrix (“Durepair”), the Company has a remaining contractual obligation to make a cash payment of $ 20.0 million in October 2026.

The obligation is recorded at its present value within accrued expenses and other current liabilities as of June 30, 2026.

The obligation is recorded at its present value within accrued expenses and other current liabilities as of September 30, 2026.

Cincinnati Facility Flood Damage

On July 17, 2026, widespread flash flooding affected the Cincinnati, Ohio area, which caused damage to the Company’s Cincinnati facility, equipment, inventory, and other assets and has resulted in operational disruption to the site.

During the three months ended September 30, 2026, the Company incurred costs associated with the restoration of the facility of approximately $ 22.2 million, primarily due to the write off of unsalvageable inventory and fixed assets as well as the cost of external service providers used for the Company’s clean-up efforts.

The Company maintains insurance coverage for damage to its facilities and inventory, as well as business interruption insurance to mitigate the adverse impact of lost revenues and remediation costs arising from the disruption of its operations.

During the three months ended September 30, 2026, the Company received an initial payment from its insurance carrier of $ 10.0 million, net of its deductible, and recognized a receivable of $ 11.4 million for claims on costs incurred to date that have been approved by the insurance carrier.

Any reimbursement of costs incurred has been recorded as a reduction of those expenses.

These amounts also include a contingent gain of $ 4.9 million recorded to other income reflecting the fair value of fixed assets damaged in the flooding over their net book values that was recognized in accordance with FASB Topic 450, Contingencies .

We have not recognized any recoveries for lost revenues, which would be presented as other income, and are actively engaged with our insurance carrier to determine amounts recoverable.

Contingent Consideration

The Company determined the fair value of contingent consideration during the six month period ended June 30, 2026 and June 30, 2025 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the six months ended June 30, 2026 and June 30, 2025 is as follows (in thousands):

Six Months Ended June 30, 2026 Contingent Consideration Liability Related to the Acquisition of:

The Company determined the fair value of contingent consideration during the nine-month period ended September 30, 2026 and September 30, 2025 to reflect the change in estimate, additions, payments, transfers and the time value of money during each period.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2026 and September 30, 2025 is as follows (in thousands):

Nine Months Ended September 30, 2026 Contingent Consideration Liability Related to the Acquisition of:

Derma Sciences (2)

4 unchanged sentences

Change in fair value of contingent consideration liabilities ( 661 ) 4 ( 1,438 ) ( 2,095 )

Balance as of June 30, 2026

Balance as of September 30, 2026

5,638 354 — 5,992

2 unchanged sentences

Total 5,638 354 — 5,992

Six Months Ended June 30, 2025 Contingent Consideration Liability Related to the Acquisition of:

Nine Months Ended September 30, 2025 Contingent Consideration Liability Related to the Acquisition of:

Derma Sciences (2)

4 unchanged sentences

Change in fair value of contingent consideration liabilities ( 1,770 ) ( 2,349 ) — ( 10,525 ) ( 14,644 )

Balance as of June 30, 2025

Balance as of September 30, 2025

$ 6,198 $ 337 $ 3 $ 25,400 31,938

6 unchanged sentences

Selling, general and administrative

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Arkis BioSciences Inc.

14 unchanged sentences

(“SIA”), the Company is required to pay to the former shareholders of SIA up to $ 90.0 million for two separate payments, which are dependent on (1) achieving certain revenue-based performance milestones in 2023, 2024, and 2025 (up to $ 50.0 million in additional payments), as well as (2) the approval by the FDA of the pre-market approval ("PMA") application for DuraSorb for certain uses by certain timing targets (up to $ 40.0 million in additional payments).

The Company estimated the fair value of the contingent consideration for the revenue based milestone to be $ 32.6 million at the acquisition date and $ 25.0 million for the PMA approval milestone at the acquisition date.

The Company estimated the fair value of the contingent consideration for the revenue

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

based milestone to be $ 32.6 million at the acquisition date and $ 25.0 million for the PMA approval milestone at the acquisition date.

The Company disbursed $ 17.9 million in the second quarter of 2026 for the 2025 performance year.

Similarly, in the second quarter of 2025, the Company disbursed $ 18.1 million related to the 2024 performance year, and in the second quarter of 2024, the Company paid out $ 12.4 million related to the 2023 performance year.

As of June 30, 2026, there were no amounts payable under the PMA approval milestone, as FDA approval of the PMA application had not been obtained by the applicable milestone date.

As of September 30, 2026, there were no amounts payable under the PMA approval milestone, as FDA approval of the PMA application had not been obtained by the applicable milestone date.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Fair Value Measurements

12 unchanged sentences

Assets and Liabilities Measured at Fair Value on a Recurring Basis

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

The Company has investments in time deposits that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, as well as certain debt obligations that are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

7 unchanged sentences

Commitments and Contingencies for additional information on these contingent consideration liabilities.

Assets and liabilities measured and recorded at fair value on a recurring basis as of June 30, 2026 and December 31, 2025 consisted of the following:

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (continued)

Assets and liabilities measured and recorded at fair value on a recurring basis as of September 30, 2026 and December 31, 2025 consisted of the following:

Dollars in thousands Fair Value

Measurement June 30, 2026 December 31, 2025

Measurement September 30, 2026 December 31, 2025

Cash and cash equivalents Level 1 $ 252,261 $ 235,048

9 unchanged sentences

Contingent consideration Level 3 5,992 26,049

Foreign currency forward contracts (not designated as hedges) Level 2 452 —

Total Liabilities:

$ 112,454 $ 167,915

There were no transfers into or out of Level 3 during the three and six months ended June 30, 2026 and 2025.

There were no transfers into or out of Level 3 during the three and nine months ended September 30, 2026 and 2025.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

3 unchanged sentences

Goodwill and Other Intangible Assets , and Note 9.

Leases and Related Party Leases , there were no non-recurring fair value measurements during the three and six months ended June 30, 2026 and 2025.

Leases and Related Party Leases , there were no non-recurring fair value measurements during the three and nine months ended September 30, 2026 and 2025.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION

1 unchanged sentence

Subsequent Events

On July 17, 2026, the Company’s manufacturing facility in Cincinnati, Ohio sustained flood damage as a result of severe weather conditions.

The flooding caused damage to the facility, equipment, inventory and other assets and resulted in operational disruptions at the site.

The Company is currently evaluating the extent of the damage and has not completed its assessment of the financial impact of the event.

At the date the financial statements were issued, the Company is unable to reasonably estimate the total losses that may be incurred.

The Company maintains insurance coverage for property damage and business interruption losses and is actively working with its insurance carriers to assess available coverage and potential recoveries.

Because the event occurred after the balance sheet date, the accompanying condensed consolidated financial statements do not reflect any adjustments related to this event.

Acquisition of Assets from Greer Manufacturing, Inc.

In September 2026, the Company entered into an asset purchase agreement with Greer Manufacturing, Inc.

(“Greer”), an existing supplier and specialty provider of precision metal machining services, to acquire all of the manufacturing assets of Greer for total consideration of $ 15.0 million in cash at closing, subject to customary purchase price adjustments related to inventory balances transferred to the Company.

The Company will account for the acquisition of Greer as a business combination, and in accordance with FASB Topic 805, Business Combinations , will record the assets acquired at their fair values as of the acquisition date.

Greer’s results of operations will be reported in the Company’s Neurosurgery reportable segment from the date of acquisition.

On October 5, 2026, the Company completed the acquisition of all of the manufacturing assets of Greer Manufacturing, Inc.

for $ 15.0 million in cash.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements